Patent ID: 10156577

Abstract:
The present invention provides a novel marker for diagnosing fibromyalgia syndrome (FMS). More specifically, the present invention provides a method for diagnosing FMS, comprising measurement of (1) the relative frequency of MAITs to the total T cells in a sample; or (2) the expression level of one or more surface antigens selected from the group consisting of CD4, CD8, CCR4, CCR7, CXCR1, NKp80, CD150, CD107a, CD8β, CD44 and CXCR4 for MAITs in a sample, wherein the sample is a biological sample collected from a human; and a diagnosis kit for FMS, comprising a means for measuring (1) the relative frequency of MAITs to the total T cells in a sample; or (2) the expression level of one or more surface antigens selected from the group consisting of CD4, CD8, CCR4, CCR7, CXCR1, NKp80, CD150, CD107a, CD8β, CD44 and CXCR4 for MAITs in a sample, wherein the sample is a biological sample collected from a human.